The global biotech API manufacturing services market, valued at US$ 38.9 Billion in 2022, is projected to grow at a CAGR of 7.1% from 2023 to 2031, surpassing US$ 73 Billion by 2031. biotech API ...

A push to reshore some drug production and progress in advanced manufacturing technologies have been prominent trends this year, industry leaders say.

Just weeks after announcing a deal to sell its antibiotics manufacturing in the U.S. to Neopharma, India’s Dr. Reddy’s Laboratories says it will now unload its API manufacturing business in Jeedimetla ...

EAST RUTHERFORD, N.J., Oct. 22, 2025 /PRNewswire/ -- Cambrex, a leading global contract development and manufacturing organization (CDMO), today announced a $120 million investment to expand its U.S.

“Our customers, in partnership with federal and state agencies, are reshoring drug manufacturing in the U.S., the world’s largest pharmaceutical market. Local API production is vital for supply chain ...

During the last decade the business landscape for Active Pharmaceutical Ingredient (API) manufacturing has drastically changed. While significant price erosion has taken place, regulatory requirements ...

Hyderabad, India – March 12, 2013 – Neuland Laboratories Ltd., (NSE:NEULANDLAB; BOM:524558) a pharmaceutical manufacturer providing active pharmaceutical ingredients (APIs), complex intermediates and ...

(MENAFN- IMARC Group) Setting up an API Manufacturing facility necessitates a detailed market analysis alongside granular insights into various operational aspects, including unit processes, raw ...